Leerink Partnrs Issues Positive Outlook for Certara Earnings

Certara, Inc. (NASDAQ:CERT - Free Report) - Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for shares of Certara in a note issued to investors on Monday, April 14th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.07 per share for the quarter, up from their prior forecast of $0.05. The consensus estimate for Certara's current full-year earnings is $0.28 per share.

Several other research firms have also commented on CERT. William Blair reiterated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Barclays reduced their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird lifted their price objective on Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. KeyCorp increased their target price on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Finally, TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 price target for the company. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $15.17.

Certara Price Performance

CERT stock traded down $0.14 during midday trading on Wednesday, hitting $14.01. 508,905 shares of the stock were exchanged, compared to its average volume of 1,185,989. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of -70.05, a PEG ratio of 9.29 and a beta of 1.64. Certara has a fifty-two week low of $8.64 and a fifty-two week high of $17.94. The stock's 50-day moving average price is $11.62 and its 200-day moving average price is $11.47.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently bought and sold shares of CERT. Versant Capital Management Inc boosted its stake in shares of Certara by 218.8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares during the period. Venturi Wealth Management LLC lifted its holdings in Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN boosted its position in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Certara during the fourth quarter worth about $47,000. Finally, Blue Trust Inc. lifted its stake in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.